Interpretation of the latest guidelines in the treatment of gastrointestinal neuroendocrine neoplasms.
- Author:
Luohai CHEN
1
;
Jie CHEN
2
;
Zhiwei ZHOU
3
Author Information
1. Department of Digestive Internal, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
2. Department of Digestive Internal, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. chen0jie@hotmail.com.
3. Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncoogy in South China, Collaborative Innovative Center for Cancer Medicine, Guangzhou 510060, China. zhouzhw@sysucc.org.cn.
- Publication Type:Journal Article
- MeSH:
Gastrointestinal Neoplasms;
chemistry;
therapy;
Humans;
Neuroendocrine Tumors;
therapy;
Pancreatic Neoplasms;
Receptors, Somatostatin
- From:
Chinese Journal of Gastrointestinal Surgery
2016;19(11):1201-1204
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine neoplasms(NEN) is a rare group of tumors with gastrointestinal tract as one of the most common primary locations. The most commonly used guidelines are proposed by European Neuroendocrine Tumor Society (ENETS) and National Comprehensive Cancer Network(NCCN) respectively, while the management of gastrointestinal NEN is generally identical in these two guidelines. Surgery is still the sole curative method which should be considered as the first choice of locoregional NEN. Otherwise, 40% to 50% of patients manifests metastatic disease when diagnosed. Hence, somatostatin analogs, targeted drugs, chemotherapy, and peptide receptor radionuclide therapy should be used comprehensively, especially for unresectable lesions. Therapeutic decision making should be based on the tumor location, functional status, tumor grade, tumor stage, somatostatin receptor status and adverse effect of drugs, etc.
